Swiss Life

PriceHubble was founded to bring transparency into real estate markets globally. We provide insights & solutions to our clients, allowing them to take smarter real estate decisions and enabling them to boost critical performance metrics in their business (e.g. client conversion, retention or rental yield). Since then, PriceHubble has gathered a unique team of data scientists, engineers and seasoned entrepreneurs to provide its clients the most advanced real estate insights, seamlessly integrated into their daily business processes. As a B2B Company, PriceHubble addresses banks, asset managers, developers, property managers and real estate agents with its digital solutions. PriceHubble is privileged to be backed by world class investors. More than 60 people are working for PriceHubble, located in Zürich, Paris, Berlin and Tokyo, and operate in 5 countries already. We are always looking for the best talents to join this exciting journey.

LaFinBox is a free and secure app that manages your money in all your financial institutions. LaFinBox was created in 2015 on the initiative of Swiss Life, a leading player in the insurance and wealth management market. Founded in 1857, the group is one of Europe's leading providers of comprehensive solutions in global pensions and finance. Through a comprehensive approach, Swiss Life advisers support individuals and businesses in a variety of areas: life insurance, private banking, financial management, health, welfare, and property damage. They offer their customers a wide range of personalized solutions, adapted to the needs and evolutions of each, in the long term. LaFinBox centralizes all financial and investment support: current accounts, bank cards, loans, passbooks, employee savings, life insurance, PEA, mortgage.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Phenex Pharmaceuticals AG, a drug discovery and development company, focuses on small-molecule drug discovery with a special emphasis on the target class of nuclear receptors. The company’s small-molecule drug discovery targets various disease areas, including liver diseases, intestinal diseases, and cancer. Its products under research and development include retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for the treatment of autoimmune diseases; and farnesoid X receptor (FXR) agonists for the treatment of non-alcoholic steatohepatitis. The company was founded in 2002 and is based in Ludwigshafen, Germany with additional laboratories and offices in Heidelberg. Phenex Pharmaceuticals AG is a former subsidiary of Sygnis Pharma AG.

iolon, Inc., is a privately held optical networking components company. The company provides high performance tunable devices for advanced fiber optic networks. iolon s initial product is a high-powered, external cavity, tunable laser source ideal for high bit rate, long haul applications. Future product lines include tunable filters, optical switches, polarization controllers, spectral monitors and universal transponders. iolon s platform technology enables advanced automation for high volume manufacturing based on patented micro-optics, MEMS and advanced servo control technologies.

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.

bexio AG develops and offers Web based business and accounting software. The company was formerly known as easySYS AG and changed its name to bexio AG in September, 2015. bexio AG was founded in 2013 and is based in Rapperswil, Switzerland. As of July 5, 2018, bexio AG operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG.

PriceHubble was founded to bring transparency into real estate markets globally. We provide insights & solutions to our clients, allowing them to take smarter real estate decisions and enabling them to boost critical performance metrics in their business (e.g. client conversion, retention or rental yield). Since then, PriceHubble has gathered a unique team of data scientists, engineers and seasoned entrepreneurs to provide its clients the most advanced real estate insights, seamlessly integrated into their daily business processes. As a B2B Company, PriceHubble addresses banks, asset managers, developers, property managers and real estate agents with its digital solutions. PriceHubble is privileged to be backed by world class investors. More than 60 people are working for PriceHubble, located in Zürich, Paris, Berlin and Tokyo, and operate in 5 countries already. We are always looking for the best talents to join this exciting journey.

Fincentrum is among the top three financial advisory consultant companies in the Czech Republic. It focuses on continuously delivering on excellence through its high quality advisory activities and always representing its client’s interests. With its advisors and business partners the company shares values of quality financial advisory. Advisors offer their clients a choice from the largest number of financial institutions and their products, and thus they can solve practically any possible situation of the client..

Vermietet.de is an association of Berlin entrepreneurs and investors whose vision is to make real estate ownership simple and intelligent. They know from their own experience how complex the management of a property can be - and have therefore founded rented.de.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.